EcoDrugPlus

5-Hydroxytryptamine (Serotonin) Receptor 2a, Genome Duplicate A

Ensembl ID : ENSATEG00000014893
Gene Symbol: HTR2AA
2 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSATEG00000012342
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSATEG00000013369
Gene Symbol: HTR2CL1
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSATEG00000005887
Gene Symbol: HTR5AB
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a-Beta

Ensembl ID : ENSATEG00000005553
Gene Symbol: LOC113148408
3 Cross references
138 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSATEG00000002109
Gene Symbol: HTR1B
3 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSATEG00000013376
Gene Symbol: HTR1E
4 Cross references
150 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSATEG00000001062
Gene Symbol: HTR3A
1 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSATEG00000007639
Gene Symbol: HTR4
2 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSATEG00000025862
Gene Symbol: LOC113159257
2 Cross references
197 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSATEG00000022031
Gene Symbol: LOC113166739
2 Cross references
383 Possible Orthologues:

60s Ribosomal Protein L5

Ensembl ID : ENSATEG00000009015
Gene Symbol: LOC113152736
3 Cross references
457 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).